China SXT Pharmaceuticals, Inc.
SXTC
$3.94
$0.6419.50%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
--
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -34.63% | -24.81% | -15.42% | -12.50% | -9.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.63% | -24.81% | -15.42% | -12.50% | -9.74% |
| Cost of Revenue | -35.25% | -25.03% | -15.12% | -7.71% | -0.06% |
| Gross Profit | -32.28% | -24.04% | -16.48% | -26.47% | -33.68% |
| SG&A Expenses | 141.87% | 607.44% | 240.16% | 429.35% | 15.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.84% | 4,901.85% | 306.65% | 1,940.40% | 9.96% |
| Operating Income | -165.74% | -493.69% | -226.63% | -344.38% | -28.11% |
| Income Before Tax | -87.83% | -705.07% | -253.06% | -551.47% | -6.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.83% | -705.07% | -253.06% | -551.47% | -6.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.83% | -705.07% | -253.06% | -551.47% | -6.62% |
| EBIT | -165.74% | -493.69% | -226.63% | -344.38% | -28.11% |
| EBITDA | -171.31% | -467.24% | -222.80% | -323.20% | -37.54% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |